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Denosumab is a more cost-effective treatment alternative in an elderly PMO pop-
ulation. Compared to no treatment, zoledronic acid, and alendronate, denosumab
can improve care in elderly PMO patients above 75 years and at the same time
lower overall treatment costs in Sweden.
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OBJECTIVES: To determine the cost-effectiveness of biologic drugs for moderate to
severe psoriatic arthritis (PsA) using a 40-year German health care perspective.
METHODS: A network meta-analysis of 8 biologics RCTs determined short-term
efficacy using Psoriasis Area and Severity Index 75% (PASI75) and American College
of Rheumatology (ACR) responses and Health Assessment Questionnaire (HAQ)
and PASI improvements. Published evidence and assumptions were used to predict
long-term efficacy using a decision analytic model. Costs included drug acquisi-
tion, administration, monitoring, and hospitalisation. Incremental cost-effective-
ness ratios (ICERs) were calculated using Quality Adjusted Life Years (QALYs), func-
tion (HAQ-adjusted life years), and years in PASI75 response. RESULTS: For the
QALY analysis, golimumab was extended dominated by adalimumab. The incre-
mental costs and QALYs for adalimumab vs. palliative care were €32046 and 0.671,
producing an ICER of €47728/QALY. Etanercept was estimated to provide margin-
ally more QALYs (0.060) at an additional €3461 (ICER of €57380/QALY vs. adali-
mumab). Although infliximab was estimated to give the most QALYs (0.031 more
than etanercept), the cost was an additional €8046 (ICER for infliximab of €260940/
QALY vs. etanercept). Results for the HAQ-adjusted life year analysis were similar,
where adalimumab (€293/HAQ life year) had similar results in comparison to etan-
ercept (€292/HAQ life year). For years in PASI75 response, etanercept became dom-
inated, golimumab gave 2.308 incremental PASI75 life years at an incremental cost
of €29463 (ICER of €12765/PASI75 life year vs. palliative care), adalimumab gave
2.704 incremental PASI75 life years at an incremental cost of €32064 (ICER of €11851/
PASI75 life year vs. palliative care), and infliximab became the optimal strategy
with 4.407 incremental QALYS at an additional €43553 (ICER of €9883/PASI75 life
year vs. palliative care). CONCLUSIONS:Using QALYs, which combine the skin and
joint aspects of disease, adalimumab and etanercept were the most cost-effective
biologic strategies; infliximab gave marginally more benefit at a much higher cost.
PMS38
COST-EFFECTIVENESS OF TAPENTADOL FOR SEVERE CHRONIC NON-CANCER
PAIN IN BELGIUM
Obradovic M1, Ikenberg R2, Hertel N3, Liedgens H1
1Grünenthal GmbH, Aachen, Germany, 2IMS Health, Munich, Germany, 3IMS Health, London, UK
OBJECTIVES: To assess the cost-effectiveness of tapentadol prolonged release
compared to morphine, oxycodone, hydromorphone, transdermal buprenorphine
[TDB], and transdermal fentanyl [TDF] for the treatment of severe chronic non-
cancer pain in Belgium. METHODS: A one year Markov transition state model with
4-week cycles was built. Four health states were defined: ‘no withdrawal and no
adverse events treated’, ’occurrence of adverse events (AEs) with need for medical
treatment’, ’withdrawal due to AEs’, and ‘withdrawal due to lack of efficacy’. Pa-
tients who were lacking efficacy or had poor tolerability switched to an alternative
2nd line opioid (oxycodone, morphine, hydromorphone, TDB or TDF). 3rd line ther-
apy was the absorbing state. Data regarding efficacy, tolerability and utility values
(EQ-5D) were derived from clinical trials and published literature. Switch rates to
2nd line therapies and resource consumption were estimated by clinical experts.
Costs were calculated from the health care payer perspective including patients’
co-payments as stated in the Belgium pharmacoeconomic guidelines. One-way,
scenario, and probabilistic sensitivity analyses were conducted. RESULTS: Com-
pared to oxycodone (direct comparison data), tapentadol had almost the same cost
but higher effectiveness, resulting in the incremental cost-effectiveness ratio
(ICER) of 6 EUR per QALY gained. The ICERs of tapentadol versus TDB, TDF, hydro-
morphone and morphine equaled to 2,407, 5,811, 19,852, and 23,182 EUR per QALY
gained, respectively. In the univariate sensitivity analysis, resource consumption,
probabilities and utilities were varied for 50%, 20% and 10%, respectively.
Conclusions about the cost-effectiveness of tapentadol remained robust, especially
when compared to oxycodone, TDF and TDB, which account for ca. 90% of the total
strong opioid market in Belgium. The ICER in these cases did not exceed 10,000 EUR
per QALY gained. CONCLUSIONS: To improve pain relief and quality of life in
patients with severe chronic pain tapentadol appears to be the favourable and
cost-effective treatment option in Belgium.
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OBJECTIVES: Currently, anti-TNF monoclonal antibodies are the mainstay of
therapy in patients with active rheumatoid arthritis (RA) and inadequate response
to methotrexate (MTX) alone. The purpose of this analysis is to evaluate the cost-
effectiveness of certolizumab pegol (CZP) versus other anti-TNF (adalimum-
ab[ADA], infliximab [INF] and etanercept [ETA]) as adjunctive therapy to MTX from
the perspective of the Brazilian private health care system. METHODS: Cost-effec-
tiveness for 52 weeks of treatment was evaluated based on the ACR20 response rate
at week 24 based on main published RCTs for each anti- TNF. An indirect compar-
ison was performed using Glenny et al method1. Annual drug costs for each aTNF
were calculated from their published ex-factory prices and their recommended
dosing schedule in the Brazilian product information. For the calculation of the
annual INF cost, the initial weight of the patient assumed for the model was as-
sumed to be 65Kg, with no increment of the doses after 22 weeks. Results are
presented in USD (June 11th, 2012 exchange rate) annual costs and incremental
cost-effectiveness ratios (ICER’s). A sensitivity analysis was made on price discount
rate. RESULTS: Annual costs were estimated in USD $12,619, USD $39,305, USD
$24,267 and USD $35,617 for CZP, ADA, INF and ETA, respectively. Adjusted by
indirect comparison of ACR20 response were 77% for CZP and 67%, 61% and 45%
for ADA, INF and ETA, respectively. The cost effective ratio was USD $16,484 for
CZP and USD $79,742, USD $59,326, USD $40,299 for ETA, ADA and INF respec-
tively. The cost-effectiveness analysis demonstrated that CZP was a dominant
strategy compared with ADA, INF and ETA. CONCLUSIONS: Certolizumab pegol
(CZP) is a cost- saving anti-TNF option for treating RA from a Brazilian private
health care perspective.
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OBJECTIVES: Cost-effectiveness of denosumab versus other treatments in MOP in
 75-year-olds in Sweden was evaluated from a third-party payer perspective.
METHODS: A lifetime cohort Markov model was developed with seven health
states: well, hip fracture, vertebral fracture, other osteoporotic fracture, post hip
fracture, post vertebral fracture, and dead. During each cycle, patients could have
a fracture, remain healthy, remain in a post fracture state or die. Background frac-
ture risks, mortality rates, persistence rates, utilities, medical and drug costs were
derived using published sources. BMD improvements have been shown to be sim-
ilar across MOP and post-menopausal osteoporotic (PMO) populations; therefore in
the absence of well-powered trials evaluating fracture risk reduction in MOP, effi-
cacy was obtained from studies in PMO women. Lifetime expected costs and qual-
ity-adjusted life-years (QALYs) were estimated for denosumab, generic alendro-
nate, generic risedronate, ibandronate, zoledronate, strontium ranelate and
teriparatide. On average, patients in the model were 78 year-old men, with bone
mineral density T-score-2.12 and prevalent vertebral fracture of 23%. In the base-
case, the model assumed patients could receive treatment effects up to 5 years
after discontinuation, except on teriparatide (only 2 years). Costs and QALYs were
discounted at 3% annually. Extensive sensitivity analyses were conducted.
RESULTS: Total lifetime costs for denosumab, alendronate, zoledronate, strontium
ranelate, risedronate, ibandronate and teriparatide were €31,324, €34,834, €35,592,
€35,939, €36,008, €37,211 and €38,632, respectively. Total QALYs were 5.22, 5.12,
5.15, 5.12, 5.11, 5.09 and 5.19, respectively. Denosumab dominated all treatments by
having lower costs and higher QALYs. Denosumab dominated generic alendronate
(next least expensive strategy) in the one-way sensitivity analyses also. The prob-
ability of denosumab being cost-effective compared to the other treatments at a
threshold of €66,000/QALY was 99.0%. CONCLUSIONS: Denosumab dominated al-
most all comparators, including generic bisphosphonates in the Swedish MOP pop-
ulation  75 years-old.
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OBJECTIVES: To assess the cost-effectiveness of denosumab and zoledronate in
preventing fractures related to osteoporosis in postmenopausal women from the
private health care sector perspective in Brazil. METHODS: A previously validated
Markov model comprising eight health states (no fracture, hip, vertebral, wrist and
other osteoporotic fractures, post hip and post vertebral fractures, and death)
quantified lifetime costs and benefits within six-month intervals. Analyzed popu-
lation consisted of postmenopausal women 72 years. Age-related risk fracture
was modeled and fracture-specific risk reductions of each targeted therapy were
computed. Efficacy data were derived from published randomized clinical trials.
The analysis included direct costs using ex-factory drug prices. Medical and labo-
ratory costs came from the Brazilian Medical Association reimbursement list. Frac-
ture-related (i.e., hospitalization, surgery) and follow-up (i.e., rehabilitation) costs
were extracted from a private health care database (BI2im). Costs were reported in
2012 Brazilian currency (1BRL0.52USD). Outcomes assessed were 10-year fracture
event incidence and quality-adjusted life years (QALYs). Costs and benefits were
discounted 5% yearly. Univariate and multivariate (probabilistic) sensitivity anal-
yses tested model robustness. RESULTS: Average morbidity costs were BRL2,722
and BRL2,839 for denosumab and zoledronate, respectively. Intervention costs
were BRL5,153 for denosumab and BRL5,481 for zoledronate. Lifetime cost differ-
ence between alternatives was BRL446 per patient treated. Ten-year fracture inci-
dence was lower with denosumab: reductions of 0.5% and 1.5% for hip and verte-
bral fractures, respectively, over zoledronate. Average QALYs were 6.861 and 6.841
for denosumab and zoledronate. Denosumab reduced fracture incidence and im-
proved QALYs at a lower cost. Denosumab remained cost-efffective after changes
in individual model parameters (up to 20% variability), considering a willingness-
to-pay of BRL57,000/QALY gained (3x Brazilian GDP/capita). Multivariate sensitivity
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analysis, showed 89.2% of iterations favored denosumab. CONCLUSIONS: Deno-
sumab was cost-effective over zoledronate from the private health care setting
perspective in Brazil, adding gains in benefits at a lower cost in preventing osteo-
porotic fractures in postmenopausal women.
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OBJECTIVES: To explore the cost-utility of adding tocilizumab (TCZ) monotherapy
to current monotherapy treatment sequences in moderate/severe adult rheuma-
toid arthritis (RA) patients with inadequate response to one or more disease-mod-
ifying antirheumatic drugs (DMARD-IR) and intolerance/contra-indication to
methotrexate (MTX) in Portugal. METHODS: A cost-utility analysis was conducted
with a societal perspective. The analysis considered two scenarios: a treatment
sequence starting with TCZ followed by two tumor necrosis factor inhibitors (anti-
TNF), adalimumab (ADA) and etanercept (ETA) and palliative care (PC) - scenario
1 - or ETA, ADA and PC - scenario 2 - compared to the same treatment sequence
without TCZ. Patients characteristics (age, starting HAQ-DI score and gender) were
based on TCZ randomized clinical trial (RCT) data in monotherapy. ACR response
data for the other biologic treatments were sourced from corresponding published
RCTs in monotherapy. A mapping model was used to assign QALYs to patients
based on HAQ-DI scores and EQ-5D collected in other RCTs (Kremer J, 2008; Smolen
JS, 2008). Resource utilization was estimated based on a Portuguese rheumatolo-
gists= expert panel. Unit costs were obtained from Portuguese official sources. Costs
and QALYs were discounted annually at 5%. Uncertainty around the model key
parameters was explored via probabilistic sensitivity analysis (PSA). RESULTS: The
model estimated that the treatment sequences starting with TCZ result in higher
QALYs and additional costs versus comparator sequences. The incremental cost-
effectiveness ratios (ICER) in both scenarios is below a threshold of 30.000€ per
QALY gained. Sensitivity analysis and PSA showed that results are robust to pa-
rameter changes. CONCLUSIONS: Results of this analysis suggest that TCZ in
monotherapy, added as first line biologic to currently used anti-TNF mono-
therapy sequences, represents an efficacious and cost-effective alternative to
sequences currently used for treating MTX intolerant/contra-indicated RA pa-
tients in Portugal.
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OBJECTIVES: To estimate the cost-effectiveness of TCZ vs. ADA used as mono-
therapy (mono) for RA from the U.S. payer perspective. METHODS: We compared
TCZ (8mg/kg every 4wks) mono vs. two doses of ADA mono: 1) 40mg weekly, 2)
40mg every 2wks. TCZ and ADA every 2wks efficacy was from the ADACTA trial;
ADA weekly efficacy was estimated using data from ADACTA and a 2004 van de
Putte study. For the 6-month trial period, we calculated incremental cost per addi-
tional ACR responder, and low disease activity score (LDAS) achieved for TCZ vs.
ADA. We also used a patient-level simulation model to estimate lifetime incremen-
tal cost per quality-adjusted life year (QALY) of initiating treatment with TCZ vs.
ADA mono; both followed by etanercept-certolizumab-palliative care. Non-re-
sponders discontinue at 6 months; responders experience a constant probability of
discontinuation thereafter. Discontinued patients go to the next treatment in the
sequence. ACR responses are linked to HAQ, which is mapped to utility to estimate
QALYs (Diamantopoulos 2012). Costs include drug treatment, monitoring, and di-
rect medical resource utilization (derived from HAQ; Kobelt 1999). Costs and QALYs
were discounted at 3%. Sensitivity analyses were performed. RESULTS: TCZ
8mg/kg mono had higher ACR responses and QALYs and lower costs compared
with ADA mono 40mg weekly. Compared with ADA 40mg every 2wks, the 6-month
incremental cost for TCZ ranged from $2,077/additional LDAS achiever to $4,509/
additional ACR70 responder; in the lifetime model the ICER was $49,195/QALY. In
one-way sensitivity analyses, results were most sensitive to changes in drug costs
and ACR responses. CONCLUSIONS: TCZ (8mg/kg every 4wks) mono dominates
(more effective and less costly) ADA (40mg weekly) mono and is cost-effective
compared to ADA (40mg every 2wks) mono, from a US payer perspective, in pa-
tients with severe RA for whom methotrexate treatment is not appropriate.
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OBJECTIVES: To estimate the cost-effectiveness of alendronate therapy for corti-
costeroid-induced osteoporosis in postmenopausal women with rheumatoid ar-
thritis in Japan. METHODS: A Markov model with six health states (no fracture,
post-vertebral fracture, post-hip fracture, post-vertebral and hip fracture, bedrid-
den, and death) was developed to predict lifetime costs and quality-adjusted life
years (QALYs) of five years of alendronate therapy versus no anti-osteoporotic
therapy in rheumatoid arthritis patients without fracture history. Fracture risk
associated with age and bone mineral density (BMD) was derived from epidemio-
logic studies in Japan. For the base-case analysis, we ran the model with age of 65
and BMD 70% of the young adult mean (YAM). Probabilistic sensitivity analysis was
performed to assess parameter uncertainty. RESULTS: Compared with no anti-
osteoporotic therapy, alendronate therapy cost an additional US$1,255 per person
and conferred an additional 0.026 QALYs, resulting in an incremental cost-effec-
tiveness ratio (ICER) of US$48,260 per QALY gained in 65-year-old patient with BMD
70% of YAM. In 70- and 75-year-old women, the ICER were estimated to be
US$32,473 and US$20,255 per QALY gained, respectively. Appling a willingness to
pay threshold of $60,000 per QALY, the probability of being cost-effective was es-
timated to 66.2 %, 92.7%, and 99.9% in 65-, 70-, and 75-year-old women with BMD
70% of YAM, respectively. CONCLUSIONS: Anti-osteoporotic therapy for cortico-
steroid-induced osteoporosis in postmenopausal women with rheumatoid arthri-
tis would be cost-effective in terms of Japan health care system.
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OBJECTIVES: There is evidence supporting the effectiveness of both exercise ther-
apy and manual therapy for hip and knee osteoarthritis (OA), but no clinical trials
or economic evaluations have been reported of their use alone or in combination
compared against usual medical care.METHODS:We conducted a cost-utility anal-
ysis alongside a randomized controlled trial. Adults meeting the American College
of Rheumatology criteria for hip or knee OA were randomly allocated to either: a)
exercise therapy; b) manual therapy; c) combined exercise therapy and manual
therapy; or d) usual medical care only. Changes in the Western Ontario and Mc-
Master (WOMAC) osteoarthritis index, physical performance measures, quality ad-
justed life years (QALY), and economic costs (presented in 2009 NZD) were assessed
at 12 months, blind to group allocation. Incremental cost-utility ratios (ICER) with
95% CIs and cost-effectiveness acceptability curves were reported, from both
health care system and societal perspectives. RESULTS: Of 206 participants re-
cruited, 193 (93.2%) were retained at follow-up. Intention-to-treat analysis showed
effect sizes for WOMAC score changes at one year compared with the usual care
group of 0.53 (Cohen’s d; 95% CI .14, .92) for manual therapy alone, 0.32 (-.07, .71) for
exercise therapy alone, and 0.31 (-.09, .70) for combined exercise therapy and man-
ual therapy. QALY gain and physical performance test outcomes significantly fa-
voured the exercise therapy group. Exercise therapy resulted in incremental cost-
utility ratios regarded as cost-effective at a willingness-to-pay threshold of 2x GDP
per-capita, but was not cost saving. Manual therapy was cost saving relative to
usual care from the societal perspective.CONCLUSIONS: Both exercise physiother-
apy and manual physiotherapy, but not combined therapy, provided incremental
benefit over usual care alone at one year follow-up. From the perspective of the
New Zealand health system, exercise therapy was best value, and from the per-
spective of society, manual therapy saved costs.
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OBJECTIVES: The treatment of rheumatoid arthritis (RA) is usually initiated with
disease-modifying anti-rheumatic drugs (DMARDs). In patients who do not tolerate
or respond to DMARDs, treatment with a biologic agent may be considered. This
study aimed to estimate the cost effectiveness of adalimumabmethotrexate
(ADAMTX) relative to standard DMARD therapy for treating early- and late-stage
RA in Italy. METHODS: Separate discrete event simulations were performed to
model the clinical and treatment pathways of early and late RA. Patients’ clinical
course was modeled as a function of baseline characteristics, treatment efficacy,
risks of adverse events, treatment withdrawals, and death. Treatment efficacy was
based on American College of Rheumatology (ACR) response, which was translated
into Health Assessment Questionnaire (HAQ) scores to facilitate the assignment of
costs and utilities. Survival, quality-adjusted life years (QALYs), and direct medical
costs were estimated over a lifetime. Inputs of demographics, treatment efficacy,
the ACR-HAQ relationship, and utility scores were extracted from several
ADAMTX trials; risks of adverse events, withdrawal rates, prices, and resource
use from the literature; and life expectancy from Italian life tables. Assumptions
regarding resource use and HAQ progression were consistent with published RA
models. RESULTS: For early RA, the incremental cost-utility ratio (ICUR) for
ADAMTX over DMARDs-only treatment (after failing two doses of MTX and fol-
lowed by rescue therapy) was estimated to be €15,770/QALY (3.37 QALYs gained
and €53,100 incremental costs). For late-stage RA, the ICUR for ADAMTX relative
to DMARDs only (after failing three doses of MTX and followed by rescue therapy)
was estimated to be €20,129/QALY (1.84 QALYs gained, €37,081 incremental costs).
Sensitivity analyses indicated that ADAMTX was cost effective over a range of key
parameters. CONCLUSIONS: The results of these simulations indicate that treat-
ment of early and late RA with ADAMTX is cost effective relative to DMARDs-only
treatment in an Italian setting.
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